According to the Zhitong Finance App, Sunflower Pharmaceutical (002737.SZ) announced that the company decided to use 780,000 yuan of its own capital to purchase 100% of the total shares of Heilongjiang Dongxu Pharmaceutical Co., Ltd. (“Dongxu Pharmaceutical”) owned by natural persons Yang Dongxu and Yang Huaizhou (corresponding registered capital of 5 million yuan). The company's acquisition aims to promote the division and independent operation of each business segment of the marketing system, mobilize organizational efficiency, and improve operational efficiency. After the transaction is completed, Dongxu Pharmaceutical will become a wholly-owned subsidiary of the company and included in the scope of the company's consolidated statements.

According to the Zhitong Finance App, Sunflower Pharmaceutical (002737.SZ) announced that the company decided to use 780,000 yuan of its own capital to purchase 100% of the total shares of Heilongjiang Dongxu Pharmaceutical Co., Ltd. (“Dongxu Pharmaceutical”) owned by natural persons Yang Dongxu and Yang Huaizhou (corresponding registered capital of 5 million yuan). The company's acquisition aims to promote the division and independent operation of each business segment of the marketing system, mobilize organizational efficiency, and improve operational efficiency. After the transaction is completed, Dongxu Pharmaceutical will become a wholly-owned subsidiary of the company and included in the scope of the company's consolidated statements.